|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
22,790,000 |
Market
Cap: |
28.03(M) |
Last
Volume: |
563,483 |
Avg
Vol: |
254,033 |
52
Week Range: |
$0.502 - $7 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Durect is a biopharmaceutical company developing therapies derived from its Epigenetic Regulator Program. Larsucosterol (also known as DUR-928), a chemical entity in clinical development, is the primary candidate in Co.'s Epigenetic Regulator Program. A bioavailable small molecule, larsucosterol has been shown in both in vitro and in vivo studies to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival. Co. is conducting a double-blind, placebo-controlled Phase 2b clinical trial called AHFIRM, in which Co. is evaluating larsucosterol's life saving potential in patients with severe alcohol-associated hepatitis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
386,132 |
Total Buy Value |
$0 |
$0 |
$0 |
$249,778 |
Total People Bought |
0 |
0 |
0 |
3 |
Total Buy Transactions |
0 |
0 |
0 |
9 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Theeuwes Felix |
Chairman and CSO |
|
2016-04-26 |
4 |
B |
$1.25 |
$200,000 |
I/I |
160,000 |
3,396,314 |
2.66 |
- |
|
Hoffmann Dave |
Director |
|
2016-04-26 |
4 |
B |
$1.25 |
$250,000 |
I/I |
200,000 |
248,000 |
2.1 |
- |
|
Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
|
2016-04-26 |
4 |
B |
$1.25 |
$6,875,000 |
D/D |
5,500,000 |
19,881,546 |
2.45 |
- |
|
Theeuwes Felix |
Chairman and CSO |
|
2016-03-14 |
4 |
B |
$1.41 |
$98,950 |
I/I |
70,000 |
3,236,314 |
2.66 |
- |
|
Blaschke Terrence F |
Director |
|
2016-03-14 |
4 |
B |
$1.35 |
$4,050 |
I/I |
3,000 |
3,000 |
2.1 |
- |
|
Neukernons Arnand |
Director |
|
2016-03-14 |
4 |
B |
$1.39 |
$25,032 |
I/I |
18,000 |
38,000 |
2.1 |
- |
|
Brown James E |
President & CEO |
|
2016-03-10 |
4 |
B |
$1.30 |
$26,564 |
I/I |
20,000 |
70,000 |
2.66 |
- |
|
First Eagle Value In Biotechnology Master Fund, Lt |
10% Owner |
|
2016-01-11 |
4 |
B |
$1.37 |
$410,537 |
D/D |
300,100 |
14,381,546 |
2.45 |
- |
|
First Eagle Value In Biotechnology Master Fund, Lt |
10% Owner |
|
2015-09-29 |
4 |
B |
$1.80 |
$1,593,088 |
D/D |
885,049 |
14,081,446 |
2.45 |
- |
|
Neukernons Arnand |
Director |
|
2015-05-22 |
4 |
B |
$2.39 |
$48,096 |
I/I |
20,000 |
20,000 |
2.1 |
- |
|
First Eagle Value In Biotechnology Master Fund, Lt |
10% Owner |
|
2015-03-17 |
4 |
B |
$1.59 |
$106,848 |
D/D |
67,200 |
13,196,397 |
2.45 |
- |
|
Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
|
2015-03-16 |
4 |
B |
$1.66 |
$166,000 |
D/D |
100,000 |
13,129,397 |
2.45 |
- |
|
Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
|
2015-03-13 |
4 |
B |
$1.66 |
$280,208 |
D/D |
168,800 |
13,029,197 |
2.45 |
- |
|
Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
|
2015-03-12 |
4 |
B |
$1.69 |
$338,000 |
D/D |
200,000 |
12,860,397 |
2.45 |
- |
|
Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
|
2015-03-11 |
4 |
B |
$1.69 |
$676,000 |
D/D |
400,000 |
12,660,397 |
2.45 |
- |
|
Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
|
2015-03-10 |
4 |
B |
$1.74 |
$870,000 |
D/D |
500,000 |
12,260,397 |
2.45 |
- |
|
Benito Simon X |
Director |
|
2015-03-10 |
4 |
B |
$1.81 |
$72,260 |
D/D |
40,000 |
60,000 |
2.39 |
- |
|
Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
|
2015-03-09 |
4 |
B |
$1.69 |
$507,000 |
D/D |
300,000 |
11,760,397 |
2.45 |
- |
|
Arnhold & S. Bleichroeder Holdings, Inc. |
10% Owner |
|
2015-03-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,460,397 |
|
- |
|
Theeuwes Felix |
Chairman and CSO |
|
2015-03-09 |
4 |
B |
$1.62 |
$371,747 |
I/I |
225,600 |
3,166,314 |
2.66 |
- |
|
Theeuwes Felix |
Chairman and CSO |
|
2015-03-06 |
4 |
B |
$1.41 |
$595,932 |
I/I |
380,000 |
2,940,714 |
2.66 |
- |
|
Theeuwes Felix |
Chairman and CSO |
|
2014-11-21 |
4 |
B |
$1.00 |
$72,700 |
I/I |
72,700 |
2,560,714 |
2.66 |
- |
|
Theeuwes Felix |
Chairman and CSO |
|
2014-11-20 |
4 |
B |
$0.92 |
$46,943 |
I/I |
49,603 |
2,488,014 |
2.66 |
- |
|
Theeuwes Felix |
Chairman and CSO |
|
2014-11-19 |
4 |
B |
$0.88 |
$77,705 |
I/I |
86,412 |
2,438,411 |
2.66 |
- |
|
Joice Judy R |
Sr. VP Operations & Corp QAOff |
|
2014-03-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,104 |
|
- |
|
152 Records found
|
|
Page 3 of 7 |
|
|